Your search for breast cancer matches 2029 pages

Showing 201 - 250


breast cancer

11-Year Follow-up of Adjuvant Trastuzumab in the HERA Trial

In the 11-year follow-up of the HERA trial reported in The Lancet, Cameron et al found that 1 year of trastuzumab (Herceptin) following adjuvant therapy for HER2-positive breast cancer remained associated with improved disease-free and overall survival compared with observation. No additional...

breast cancer

Poor Diet During Adolescence/Early Adulthood and Risk for Premenopausal Breast Cancer

Although adolescence is a highly susceptible time for mammary carcinogenesis, few prospective studies have examined the role of adolescent diet and breast cancer risk. Now, a study investigating the association of an adolescent and early adulthood dietary pattern that promotes chronic inflammation...

breast cancer
prostate cancer
supportive care

ASCO Quality Care 2017: Mental Health Conditions Contribute to Care-Related Costs, Hospital Visits in Breast and Prostate Cancers

A new analysis of data from the U.S. Military Health System found that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with breast and prostate...

breast cancer
issues in oncology

ASCO Quality Care 2017: Study Examines Cancer Center Websites’ Information on Breast Cancer Treatment, Outcomes

As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients with breast cancer understand all their...

breast cancer

Cholesterol-Lowering Medication Use and Breast Cancer Outcome in the BIG 1-98 Trial

In a study reported in the Journal of Clinical Oncology, Borgquist et al found that use of cholesterol-lowering medication during adjuvant endocrine therapy was associated with a reduced risk of breast cancer recurrence in hormone receptor–positive women in the BIG 1-98 trial. Study Details ...

Breast Cancer

Cancer Has Made Me the Person I Am

My breast cancer diagnosis in 1993, at age 34, came at the happiest moment in my life. I had gotten married just 10 months earlier and was looking forward to the future and children. But instead of celebrating my first wedding anniversary with my husband over a romantic dinner, we were at a cancer ...

Breast Cancer

Assessment of Therapeutic Response by Intrinsic Subtype for HER2-Positive Breast Tumors

In an analysis of outcomes in the North Central Cancer Treatment Group/Alliance N9831 trial reported in the Journal of the National Cancer Institute, Edith A. Perez, MD, of the Mayo Clinic Cancer Center, and colleagues found that patients with tumors scored as HER2-enriched or luminal subtype...

Breast Cancer

Results From MONALEESA-2: Are All CDK4/6 Inhibitors Equal?

Hormone receptor–positive breast cancer is the most common subtype of breast cancer, and while endocrine therapy has long been a mainstay of therapy for these patients, treatment resistance ultimately develops. Therefore, better therapeutic approaches are needed. There are some data to suggest...

Breast Cancer

First-Line Ribociclib Prolongs Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Breast Cancer

As reported by The ASCO Post from the recent European Society for Medical Oncology Conference, first-line treatment with ribociclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), resulted in significantly longer progression-free survival vs placebo in women with hormone...

breast cancer

Chinese Trial Adds Utidelone to Capecitabine in Heavily Pretreated Patients With Metastatic Breast Cancer

In a Chinese phase III trial reported in The Lancet Oncology, Zhang et al found that adding the epothilone analog utidelone to capecitabine prolonged progression-free survival in women with heavily pretreated metastatic breast cancer refractory to both anthracycline and taxane treatment. Study...

breast cancer

More Patients With Early-Stage Breast Cancer May Be Able to Avoid Chemotherapy in the Future

Women with early-stage breast cancer who had an intermediate risk recurrence score from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study from The University of Texas MD Anderson Cancer finds. The research, published by Barcenas et al in ...

breast cancer

Olaparib Meets Primary Endpoint in OlympiAD Trial in BRCA-Mutated Metastatic Breast Cancer

On February 17, positive results were announced from the phase III OlympiAD trial comparing olaparib (Lynparza) tablets to physician’s choice of a standard-of-care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2...

Breast Cancer

New Data on Prognostic Factors, Disease Detection, Drug Toxicities, and Treatment Adherence Presented at SABCS

The San Antonio Breast Cancer Symposium (SABCS) offers state-of-the-art information on all aspects of breast cancer biology, diagnosis, and treatment, drawing an international audience of more than 7,500 physicians, researchers, and other health-care professionals from over 90 countries. Through...

breast cancer

Study Finds Suboptimal Use of Adjuvant Endocrine Therapy in Breast Cancer

In a retrospective cohort study reported in JAMA Oncology, Daly et al found that recommended use of adjuvant endocrine therapy for breast cancer improved in the United States between 2004 and 2013 but remains suboptimal. The study included data on 981,729 women with stage I to III breast cancer...

breast cancer

Effect of Scalp-Cooling Device on Hair Loss in Women Receiving Chemotherapy for Breast Cancer

An interim analysis of the SCALP trial, reported in JAMA by Nangia et al, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling. The study was stopped early on the basis of efficacy....

breast cancer

Genetic Testing and Counseling Among Women With Newly Diagnosed Breast Cancer

In a population-based study reported in a research letter in JAMA, Kurian et al found that genetic testing and genetic counseling are suboptimal among women with newly diagnosed breast cancer. Study Details The study involved 2,451 women aged 20 through 79 years diagnosed with stage 0 to II...

breast cancer

Patients With Breast Cancer With Dense Breast Tissue More Likely to Develop Contralateral Disease

Patients with breast cancer with dense breast tissue have almost a twofold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer Center. The study, published by Brewster et al in the journal Cancer, is among the...

breast cancer

Zoledronic Acid Every 12 Weeks vs Every 4 Weeks in Women With Breast Cancer and Bone Metastases

In the phase III OPTIMIZE-2 trial reported in JAMA Oncology, Hortobagyi et al found that an every-12-week schedule of zoledronic acid was noninferior to an every-4-week schedule in terms of skeletal-related event rate in women with bone metastases from breast cancer who were currently receiving...

breast cancer

Residual Cancer Burden, Breast Cancer Phenotype, and Long-Term Prognosis After Neoadjuvant Chemotherapy

In a study reported in the Journal of Clinical Oncology, Symmans et al found that residual cancer burden (RCB) after neoadjuvant chemotherapy was significantly prognostic for long-term outcome across breast cancer subtypes. Study Details The study included 5 patient cohorts from The University of ...

Breast Cancer

Serum DNA Methylation as Predictive Marker in Metastatic Breast Cancer

In the Translational Breast Cancer Research Consortium (TBCRC) 005 prospective biomarker study, reported in the Journal of Clinical Oncology by Kala Visvanathan, MBBS, MHS, of Johns Hopkins University, and colleagues, a cumulative methylation index was found to be predictive of progression-free...

breast cancer

Nearly Half of Patients Treated for Early-Stage Breast Cancer Report at Least One Severe Side Effect

Nearly half of women treated for early-stage breast cancer reported at least one side effect from their treatment that was severe or very severe, according to a new study published by Friese et al in Cancer. Although it might be expected for women undergoing chemotherapy, researchers found...

breast cancer

Accelerated Partial-Breast vs Whole-Breast Irradiation After Breast-Conserving Surgery

As reported in The Lancet Oncology by Polgár et al, 5-year late side effects and cosmetic results were similar with accelerated partial-breast irradiation (APBI) with interstitial brachytherapy vs whole-breast irradiation (WBI) after breast-conserving surgery for low-risk invasive and in...

Breast Cancer

Expert Point of View: Amber Orman, MD

Amber Orman, MD, of the Department of Radiation Oncology, Breast Section, at Moffitt Cancer Center in Tampa, Florida, who was not involved in this study, said: “This study provides guidance when deciding how best to integrate postmastectomy reconstruction and radiation therapy. This is an area...

Breast Cancer

Autologous Breast Reconstruction Associated With Fewer Complications and Failures Than Implants in Women Who Have Received Radiation

Postmastectomy radiation is becoming more commonly used to treat breast cancer, and at the same time, there is an increasing trend among women to have breast reconstruction. Until now, oncologists have had little evidence on what the best reconstruction options are in women who require radiation...

Breast Cancer

Expert Point of View: Virginia Kaklamani, MD, and Melinda L. Telli, MD

Moderator of the press conference on this study, Virginia Kaklamani, MD, of the University of Texas Health Science Center at San Antonio, agreed that an improvement in response is important. “If you are a patient with symptoms, such as a cough from lung metastases, and I give you a combination...

Breast Cancer

Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers

A randomized phase II study in women with metastatic breast cancer who have mutations in BRCA1 or BRCA2 evaluated the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to combination chemotherapy. The trial did not meet its primary endpoint.1 Hyo Sook Han, MD, of Moffitt...

Breast Cancer
Symptom Management

Randomized Trial Demonstrates Benefit of Scalp-Cooling in Prevention of Chemotherapy-Induced Hair Loss

A scalp-cooling device was found safe and effective in preventing chemotherapy-induced hair loss in women undergoing adjuvant treatment for breast cancer in an interim analysis of the first prospective, randomized trial of a modern scalp-cooling system. The study was presented at the 2016 San...

Breast Cancer

Expert Point of View: Melinda L. Telli, MD

Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University Medical Center, Palo Alto, commented on this topic for The ASCO Post. She said the results of the two studies reinforce what has been emerging about the prognostic impact of tumor-infiltrating lymphocytes. “We have known...

breast cancer

Adjuvant Letrozole vs Anastrozole in Hormone Receptor–Positive Node-Positive Early Breast Cancer

As reported in the Journal of Clinical Oncology by Smith et al, the final results of the phase III FACE trial showed no difference in disease-free or overall survival for adjuvant letrozole vs anastrozole in postmenopausal women with hormone receptor–positive node-positive early breast...

Breast Cancer

Tumor-Infiltrating Lymphocytes Prognostic in the Metastatic and Neoadjuvant Breast Cancer Settings

Studies presented at the 2016 San Antonio Breast Cancer Symposium added to growing evidence that tumor-infiltrating lymphocytes are important prognostic factors in breast cancer. One investigation evaluated their impact in advanced HER2-positive breast cancer, finding a linear relationship between...

breast cancer
survivorship

Shoshana M. Rosenberg, ScD, MPH, on Young Breast Cancer Survivors: Helping Them Cope

Shoshana M. Rosenberg, ScD, MPH, of the Dana-Farber Cancer Institute, talks about ways to help young women move from active treatment to survivorship, based on findings from focus groups in which patients discussed their unexpected physical and psychological experiences after surgery (Abstract 180).

breast cancer
survivorship

Lauren P. Wallner, PhD, MPH, on Breast Cancer Survivorship Care: Patient Preferences

Lauren P. Wallner, PhD, MPH, of the University of Michigan, discusses her findings on the type of providers women prefer when it comes to handling survivorship care after breast cancer treatment and the need to clarify and discuss provider roles with patients (Abstract 99).

survivorship
pain management
breast cancer

Sophia Kustas Smith, PhD, MSW, on Depression and Fatigue: Self-Managed in 'Reimagine'

Sophia Kustas Smith, PhD, MSW, of Duke University, discusses study findings on an online, symptom self-management curriculum, known as www.reimagine.me, employed for breast cancer survivors with chronic pain (Abstract 182).

breast cancer
symptom management

Electra D. Paskett, PhD, on Preventing Lymphedema: Results of a CALGB Study

Electra D. Paskett, PhD, of The Ohio State University Comprehensive Cancer Center, discusses an intervention that increased knowledge of lymphedema in breast cancer, and the personal story that drove her research (Abstract 104).

breast cancer
survivorship

Shawna V. Hudson, PhD, on Breast Cancer: A Quality-of-Life Program

Shawna V. Hudson, PhD, of Rutgers University, discusses a survivorship program designed to improve the quality of life for Hispanic and Latino breast cancer survivors (Abstract 183).

breast cancer

ECCO 2017: Some Patients With Early-Stage Breast Cancer May Benefit More From Breast-Conserving Therapy Than Mastectomy

Breast-conserving therapy (breast-conserving surgery combined with radiation therapy) may be superior to mastectomy in certain patients with breast cancer, according to results from the largest study on this topic to date, presented at the 2017 European Cancer Congress (Abstract 4LBA). Although...

breast cancer

ECCO 2017: Low Cause-Specific Mortality in Women Over 50 Treated for Ductal Carcinoma in Situ

Women over 50 who have been treated for ductal carcinoma in situ (DCIS) are more likely to be alive 10 years later than women in the general population, according to new research presented by Elshof et al at the 2017 European Cancer Congress (ECCO) (Abstract 173). DCIS differs from breast cancer...

breast cancer

Predicting Acute Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy

In a Dutch study reported in the Journal of Clinical Oncology, van den Bogaard et al found that a model including the volume of the left ventricle receiving 5 Gy (LV-V5) might provide improved prediction of acute cardiac events in patients with breast cancer receiving radiotherapy. Prior findings...

Breast Cancer
Issues in Oncology

Managing Breast Cancer in a Pregnant Patient

“One of the most challenging oncologic situations that I face as a clinician is the diagnosis of breast cancer in a young pregnant patient,” ­Jacqueline Jeruss, MD, PhD, Director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center, Ann Arbor, told the more than 250...

Breast Cancer

Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD

Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral density test can help identify candidates for bone-modifying agents. “We look at women who are going on...

Breast Cancer

Ibandronate Fails to Improve Disease-Free Survival in Early Breast Cancer Patients—but With Favorable Trends

Addition of the oral bisphosphonate ibandronate to endocrine therapy did not significantly improve disease-free survival in patients with early breast cancer, according to the first results from the Dutch TEAM IIb trial presented at the 2016 San Antonio Breast Cancer Symposium.1 The results were...

Breast Cancer

Breast Cancer Experts Question New Recommendations for 21-Gene Recurrence Score Assay

At the 2016 San Antonio Breast Cancer Symposium, a group of breast cancer experts made a case for using the 21-gene Oncotype DX Breast Recurrence Score Assay in node-positive patients, despite ASCO’s latest recommendations to restrict it to node-negative estrogen receptor–positive patients. The...

Breast Cancer

Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium

Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....

Breast Cancer

Expert Point of View: Steven Vogl, MD

Presentation of the PERTAIN study data by lead author Grazia Arpino, MD, PhD, was met with high interest at the 2016 San Antonio Breast Cancer Symposium. Steven Vogl, MD, of the Bronx, New York, commented, “This is a very complicated study for me, but it seems that at least half your patients got...

Breast Cancer

Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herceptin) and an aromatase inhibitor in the first-line setting significantly improved progression-free ...

Breast Cancer

Expert Point of View: Howard A. “Skip” Burris, MD

Howard A. “Skip” Burris, MD, President of Clinical Operations and Chief Medical Officer at Sarah Cannon Research Institute, Nashville, commented on the poster presentation for The ASCO Post. He said the results “fit the whole paradigm” that is desired for triple-negative breast cancer, which is to ...

breast cancer

Risk Factors for Estrogen Receptor–Positive and –Negative Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Kerlikowske et al identified risk factors for estrogen receptor–positive and –negative breast cancer using data from the Breast Cancer Surveillance Consortium. The analysis included 1,279,443 women, aged 35 to 74...

Breast Cancer

Novel Antibody-Drug Conjugate Targets Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab govitecan (IMMU-132) produced high objective response rates, many of them quite durable, in a multicenter study of heavily pretreated patients with metastatic triple-negative breast cancer, presented at the 2016 San Antonio Breast Cancer Symposium.1 Trop-2 is ...

breast cancer

Higher Intake of Grilled/Barbecued and Smoked Meat Linked to Reduced Survival After Breast Cancer

In a study reported in the Journal of the National Cancer Institute, Parada et al found that higher intake of grilled/barbecued and smoked meat may be associated with poorer overall survival in breast cancer survivors. Grilled/barbecued and smoked meat, a source of polycyclic aromatic hydrocarbon...

breast cancer

Tucatinib Shows Clinical Benefit in Phase I Trial in HER2-Positive Breast Cancer

Phase I clinical trial data published by Moulder-Thompson et al in Clinical Cancer Research reported that the investigational anticancer agent tucatinib (formerly ONT-380) showed 'notable activity' in the treatment of HER2-positive breast cancer with . The 50 women treated had disease...

Advertisement

Advertisement



Advertisement